Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation
Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation
复制标题
DOI：
10.1046/j.1365-2141.2001.02672.x
复制
发表时间：
2001-03-01
影响因子：
6.5
通讯作者：
Prentice, AG
中科院分区：
文献类型：
--
作者：
Scrivener, S;Kaminski, ER;Prentice, AG
B细胞慢性淋巴细胞白血病（B-CLL）的特征在于恶性克隆B细胞的积聚。允许这种积累的内在特性已被广泛研究和描述。然而，这是可能的增殖和生存的恶性克隆是促进破坏之间的相互作用B和T细胞，通常调节免疫系统，在这项研究中，使用流式细胞术和细胞培养技术，显着异常的表达某些关键的活化和相互作用分子的外周血T细胞的B-CLL患者被证明。特别是与正常对照相比，表达CD 25（白细胞介素2受体）（P = 0.007）、CD 28（P = 0.01）和CD 152（CTLA-4）（P = 0.001）的循环T细胞的数量显著减少。表达CD 4（P = 0.03）、CD 5（P = 0.05）和CD 11 a（P = 0.01）的循环T细胞数量也减少。在表达T细胞受体ap（P = 0.1）、CD 8（P = 0.4）、CD 54（P = 0.4）和CD 154（P = 0.5）的数量上没有差异，并且在B-CLL患者中在更多数量的循环T细胞上表达的唯一标志物是HLA-DR（P = 0.05）。这些结果表明，有一个深刻的T细胞失调，可能有助于生存的恶性B细胞在B-CLL患者和相关的自身免疫现象的疾病。
B-cell chronic lymphocytic leukaemia (B-CLL) is characterized by an accumulation of clonal malignant B cells. The intrinsic characteristics that permit this accumulation have been extensively studied and described. However, it is possible that proliferation and survival of this malignant clone is facilitated by a disruption in the interaction between B and T cells that normally regulate the immune system, In this study, using flow cytometry and cell culture techniques, marked abnormalities of the expression of certain key activation and interaction molecules on the peripheral blood T cells of patients with B-CLL were demonstrated. in particular, on comparison with normal controls, there was a marked reduction in the number of circulating T cells expressing CD25 (interleukin 2 receptor) (P = 0.007), CD28 (P = 0.01) and CD152 (CTLA-4) (P = 0.001). There was also a reduction in the number of circulating T cells expressing CD4 (P = 0.03), CD5 (P = 0.05) and CD11a (P = 0.01). There was no difference in the number expressing T-cell receptor ap (P = 0.1), CD8 (P = 0.4), CD54 (P = 0.4) and CD154 (P = 0.5), and the only marker expressed on a greater number of circulating T cells in B-CLL patients was HLA-DR (P = 0.05). These results suggest that there is a profound T-cell dysregulation that may contribute to the survival of the malignant B cells in patients with B-CLL and to the related autoimmune phenomena of the disease.